WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...

The SHOCK study (SHould we emergently revascularize ... Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of ...

It's common to experience culture shock when you're transplanted into a foreign setting. This is a normal reaction to a new environment where you are no longer in control as you have been at home. You ...

An invasive strategy is preferred in the following cases: if a skilled cath lab with surgical backup is available; in high-risk patients (those in cardiogenic shock, Killip class ≥ 3 ...